<DOC>
	<DOCNO>NCT00670033</DOCNO>
	<brief_summary>The purpose study describe safety IOP-lowering efficacy Travoprost New Formulations compare TRAVATANÂ® vehicle patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Travoprost New Formulations Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Satisfy inform consent requirement ; Diagnosed openangle glaucoma ocular hypertension ; Able discontinue use IOPlowering medication minimum 5 28 day prior Eligibility 1 Visit ; IOP measurement least 1 eye specify protocol ; Other protocolspecified inclusion criterion may apply . Females childbearing potential pregnant , breastfeeding , use highly effective birth control measure ; Any form glaucoma openangle glaucoma ; Severe central visual field loss either eye ; Chronic , recurrent severe inflammatory eye disease ; Clinically relevant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment , opinion Investigator ; Bestcorrected visual acuity ( BCVA ) worse 0.60 logarithm miniminum angle resolution ( logMAR ) ; Intraocular surgery within past 6 month ; Ocular laser surgery within past 3 month ; Any abnormality prevent reliable applanation tonometry ; Severe illness condition would make patient , opinion Investigator , unsuitable study ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>IOP</keyword>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>